2007
DOI: 10.1016/j.bmcl.2006.09.069
|View full text |Cite
|
Sign up to set email alerts
|

2,6-Quinolinyl derivatives as potent VLA-4 antagonists

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2008
2008
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 10 publications
(3 citation statements)
references
References 41 publications
0
3
0
Order By: Relevance
“…25 Compounds 12c and 12e were treated with acetyl chloride 26 to obtain their acetyl derivatives 12c′ and 12e′ , respectively (Scheme 5 ). Reduction of the nitro group 27 28 29 in 12m with H 2 and Pd/C or SnCl 2 was possible, but the obtained product was too unstable to be isolated by column chromatography. Additional efforts to react 12m by reduction and acylation to produce an amide derivative in a one-pot procedure were investigated.…”
Section: Table 1 Ic 50 Valu...mentioning
confidence: 99%
“…25 Compounds 12c and 12e were treated with acetyl chloride 26 to obtain their acetyl derivatives 12c′ and 12e′ , respectively (Scheme 5 ). Reduction of the nitro group 27 28 29 in 12m with H 2 and Pd/C or SnCl 2 was possible, but the obtained product was too unstable to be isolated by column chromatography. Additional efforts to react 12m by reduction and acylation to produce an amide derivative in a one-pot procedure were investigated.…”
Section: Table 1 Ic 50 Valu...mentioning
confidence: 99%
“…Finally, Elan has described a series of azabenzimidazolinones such as compound 64 incorporating various acyl groups selected from their own and the work of other researchers in the field in a patent application [152] . Figure 10 includes a number of structures, including the quinoline 65 [153] , bearing interesting features that are not typically associated with potent α 4 integrin antagonists. The piperazine 66 is only moderately potent in a Jurkat cell/VCAM binding assay (IC 50 : 1122 ± 250 nM), but has excellent bioavailability (F = 86%) and lower biliary clearance than many of the other analogs in the same series.…”
Section: Small Molecule Derived From N -Acylphenylalaninesmentioning
confidence: 99%
“…The development of small-molecule VLA-4 antagonists represents a promising approach to treat this class of inflammatory diseases. As a part of these efforts, UCB-108770 ( 1 ) (Figure ) was identified as a potent VLA-4 antagonist …”
Section: Introductionmentioning
confidence: 99%